Considering the role of MFG-E8 knockout in promoting liver inflammation and fibrosis, it is reasonable to expect that targeting MFG-E8 may be a promising strategy for improving NASH outcome. Here, MFGE8 is linked to metabolic dysfunction-associated steatohepatitis.